apoCIII inhibitors

apoCIII inhibitors has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Feb 27, 2026: “Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on apoCIII inhibitors

What did studies of apoCIII inhibitors find?

1

Studies of apoCIII inhibitors measured one outcome, remnant cholesterol.

Remnant cholesterol

downin humans1

1 study
  1. apoCIII inhibitors decrease remnant cholesterol in individuals with elevated plasma triglyceride levels up to 10 mmol/L (880 mg/dL) (50-80%).

    “apoCIII and ANGPTL3 and 4 inhibitors and FGF21 analogues lower remnant cholesterol levels by 50-80%”

    Reviewin individuals with elevated plasma triglyceride levels up to 10 mmol/L (880 mg/dL)

    Feasibility of remnant cholesterol as a therapeutic target for atherosclerotic cardio-vascular disease

    Expert opinion on therapeutic targets

More on Remnant cholesterol

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months